2 days ago
1
gerenme/iStock via Getty Images
Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s blood-based colorectal cancer screening tests. As part of the deal, Freenome, a biotech company, is set to receive a substantial payment of $75M in cash, which is scheduled
English (US) ·